Predicting the Oxidative Metabolism of Statins: An Application of the MetaSite® Algorithm
- 301 Downloads
This study was undertaken to examine the MetaSite algorithm by comparing its predictions with experimentally characterized metabolites of statins produced by cytochromes P450 (CYPs).
Seven statins were investigated, namely atorvastatin, cerivastatin, fluvastatin, pitavastatin and pravastatin which are (or were) used in their active hydroxy-acid form, and lovastatin and simvastatin which are used as the lactone prodrug. But given the fast lactone-hydroxy-acid equilibrium undergone by statins, both forms were investigated for each of the seven drugs. The MetaSite version 2.5.3 used here contains the homology 3D-models of CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4. In addition, we also used the crystallographic 3D-structure of human CYP2C9 and CYP3A4. To allow a better interpretation of results, the probability function P SM i calculated by MetaSite (namely the probability of atom i to be a site of metabolism) was explicitly decomposed into its two components, namely a recognition score Ei (the accessibility of atom i) and the chemical reactivity Ri of atom i toward oxidation reactions.
The current version of MetaSite is known to work best with prior experimental knowledge of the cytochrome(s) P450 involved. And indeed, experimentally confirmed sites of oxidation were correctly given a high priority by MetaSite. In particular 77% of correct predictions (including false positive but, as discussed, this is not necessarily a shortcoming) were obtained when considering the first five metabolites indicated by MetaSite.
To the best of our knowledge, this is the first independent report on the software. It is expected to contribute to the development of improved versions, but above all it demonstrates that the usefulness of such softwares critically depends on human experts.
Key wordsin silico metabolism prediction MetaSite molecular fields statins
GC and GE are indebted to the University of Turin for financial support. The authors thank Silvia Tonelli for the preliminary work carried out during her undergraduate period of study. Molecular Discovery is also acknowledged for a free license and technical support.
Supporting Information Available: Corresponding atoms in the lactone and hydroxy-acid forms together with the complete lists of PSMi, E i and R i data for all investigated compounds.
- 1.B. Testa and G. Cruciani. Structure–metabolism relations, and the challenge of predicting biotransformation. In B. Testa, H. van de Waterbeemd, G. Folkers, and R. H. Guy (eds.), Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Chemistry, Wiley-VHCA, Zurich, 2001, pp. 65–84.CrossRefGoogle Scholar
- 2.B. Testa and W. Soine. Principles of drug metabolism. In D. J. Abraham (ed.), Burger’s Medicinal Chemistry and Drug Discovery, Wiley-Interscience, Hoboken, N.J., USA, 2003, pp. 431–498.Google Scholar
- 3.P. W. Erhardt. Metabolism Databases and High. Throughput Tesing During Drug Design and Development, Blackwell Science, London, UK, 1999.Google Scholar
- 9.J. E. Penzotti, G. A. Landrum, and S. Putta. Building predictive ADMET models for early decisions in drug discovery. Curr. Opin. Drug Discov. Dev. 7:49–61 (2004).Google Scholar
- 11.D. L. Harris. In silico predictive metabolism: a structural/electronic filter method. Curr. Opin. Drug Discov. Dev. 7:43–48 (2004).Google Scholar
- 13.R. N. Hines, Z. Luo, T. Cresteil, X. Ding, R. A. Prough, J. L. Fitzpatrick, S. L. Ripp, K. C. Falkner, N.-L. Ge, A. Levine, and C. J. Elferink. Molecular regulation of genes encoding xenobiotic-metabolizing enzymes: mechanisms involving endogeneous factors. Drug Metab. Dispos. 29:623–633 (2001).PubMedGoogle Scholar
- 15.P. A. Smith, M. J. Sorich, R. A. McKinnon, and J. O. Miners. Pharmacophore and quantitative structure–activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J. Med. Chem. 46:1617–1626 (2003).PubMedCrossRefGoogle Scholar
- 24.A. M. ter Laak and N. P. E. Vermeulen. Molecular modeling approaches to predict metabolism and toxicity. In B. Testa, H. van de Waterbeemd, G. Folkers, and R. H. Guy (eds.), Pharmacokinetic Optimization in Drug Research, Wiley-VCH, Zürich, 2001, pp. 551–588.Google Scholar
- 30.B. Testa and J. M. Mayer. Hydrolysis in Drug and Prodrug Metabolism—Chemistry, Biochemistry and Enzymology, Wiley-VHCA, Zurich, 2003, pp. 493–495.Google Scholar
- 36.M. J. Garcia, R. F. Reinoso, A. Sanchez Navarrro, and J. R. Prous. Clinical pharmacokinetics of statins. Meth. Fin. Exp. Clin. Pharmacol. 25:457–481 (2003).Google Scholar
- 39.G. Cruciani, R. Vianello, and I. Zamora. Prediction of site of metabolism in humans: case studies of cytochromes P450 2C9, 2D6 and 3A4. In B. Testa, S. Kraemer, H. Wunderli-Allenspach, and G. Folkers (eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical and Computational Strategies, Wiley-VHCA, Zürich, 2005, pp. 367–379.Google Scholar
- 43.R. C. Wade, K. J. Clark, and P. J. Goodford. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. I. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 36:140–147 (1993).PubMedCrossRefGoogle Scholar
- 44.R. C. Wade and P. J. Goodford. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. II. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 36:148–156 (1993).PubMedCrossRefGoogle Scholar
- 46.MOE, version 2005.06, 2005,. Chemical Computing Group, Montreal, Quebec Canada, http://www.chemcomp.com/.
- 48.Vega, version 2.0.5., 2006, http://www.ddl.unimi.it/.
- 51.T. Sakaeda, H. Fujino, C. Komoto, M. Kakumoto, J. Jin, K. Iwaki, K. Nishiguchi, T. Nakamura, N. Okamura, and K. Okumura. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23:506–512 (2006).PubMedCrossRefGoogle Scholar
- 52.W. F. Trager. Principles of drug metabolism 1: redox reactions. In B. Testa and H. van de Waterbeemd (eds.), Comprehensive Medicinal Chemistry, 2nd Edition, Volume 5, Elsevier, Oxford, UK, 2006, pp. 87–132.Google Scholar
- 56.W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K.-F. Sewing, and U. Christians. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA-reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos. 27:173–179 (1998).Google Scholar
- 57.B. Testa. The Metabolism of Drugs and Other Xenobiotics—Biochemistry of Redox Reactions, Academic, London, UK, 1995.Google Scholar
- 59.B. Testa and S. Kraemer. The biochemistry of drug metabolism. An introduction. Part 2. Redox reactions and their enzymes. Chem. Biodivers. (2007) (in press).Google Scholar
- 61.J. Cejka, B. Kratochvil, I. Cisarova, and A. Jegorov. Simvastatin. Acta Crystallogr. C59:o428–o430 (2003).Google Scholar
- 62.F. H. Allen. The Cambridge structural database: a quarter of a million crystal structures and rising. Acta Crystallogr. B58:380–388 (2002).Google Scholar